Global Leading Market Research Publisher QYResearch announces the release of its latest report “SND1 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global SND1 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for SND1 Antibody was estimated to be worth US32millionin2025andisprojectedtoreachUS32millionin2025andisprojectedtoreachUS48 million by 2032, growing at a CAGR of 6.0% from 2026 to 2032. For biomedical researchers, laboratory procurement managers, and cancer biology scientists, the core business imperative lies in selecting SND1 antibodies that address the critical need for detecting and quantifying Staphylococcal Nuclease Domain-Containing Protein 1 (SND1, also known as Tudor-SN, p100 co-activator, EBNA2 co-activator), a multifunctional protein involved in transcription regulation (co-activator for STAT6, STAT5, androgen receptor), RNA interference (RISC complex component, microRNA degradation), mRNA splicing, and DNA repair. SND1 is overexpressed in various cancers (hepatocellular carcinoma (HCC), breast, prostate, colon, gastric, glioblastoma) and plays a role in viral replication (HIV-1, Epstein-Barr virus (EBV)), making it a potential biomarker and therapeutic target. SND1 antibody LS-C669584 is a rabbit polyclonal antibody (available as Biotin conjugates) that binds human SND1 (and cross-reactive mouse, rat, other species) validated for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), and ELISA (Enzyme-Linked Immunosorbent Assay). Conjugates include Biotin (for streptavidin detection), HRP (horseradish peroxidase), FITC (fluorescein isothiocyanate), and agarose (for IP). Applications: cancer research (SND1 as oncogene), virology (HIV, EBV), RNA biology (RISC function), and drug discovery (SND1 inhibitor development).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985631/snd1-antibody
The SND1 Antibody market is segmented as below:
Merck
Thermo Fisher Scientific
GeneTex
LifeSpan BioSciences
Leading Biology
RayBiotech
ProSci
Bio-Rad
Aviva Systems Biology
Novus Biologicals
ABclonal Technology
Bethyl Laboratories
Proteintech Group
St John’s Laboratory
Biobyt
Jingjie PTM BioLab
Wuhan Fine Biotech
Beijing Solarbio
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
1. Market Drivers: Cancer Research Funding, RNA Interference Studies, and Viral Pathogenesis
Several powerful forces are driving the SND1 antibody market:
Cancer biology and oncology research – SND1 overexpression in liver, breast, prostate, colon cancers. Antibody for IHC tissue microarray (TMA), patient prognosis correlation. Targeting SND1 for therapeutic intervention.
RNA interference (RNAi) and microRNA (miRNA) studies – SND1 component of RISC (RNA-induced silencing complex), regulates miRNA stability, target gene silencing. Antibody for IP-MS (mass spectrometry) identification of protein interaction partners (GW182, AGO2).
Viral replication and infectious disease – HIV-1 Tat protein interacts with SND1; EBNA2 (Epstein-Barr virus) co-activator. Antibody for viral pathogenesis research.
Recent market data (December 2025): According to Global Info Research analysis, polyclonal SND1 antibodies dominate with approximately 65% revenue share (higher sensitivity, multiple epitopes, cost-effective). Monoclonal 35% share (superior specificity, batch consistency). Western Blot (WB) largest application (40% share) (protein expression, knockdown efficiency validation). Immunohistochemistry (IHC) 25% share (tissue localization, cancer progression). Immunoprecipitation (IP) 15% share (protein-protein interaction, complex purification). Immunofluorescence (IF) 10% share (cellular localization). ELISA 5% share. Others 5%. North America largest market (45% share) (NIH funding, biotech R&D). Europe 30% share. Asia-Pacific 20% share. Merck, Thermo Fisher, Abcam, LifeSpan, Novus, Proteintech leading suppliers.
2. Antibody Types and Specifications
| Type | Host | Clonality | Specificity | Sensitivity | Batch Consistency | Price (100µL) | Share |
|---|---|---|---|---|---|---|---|
| Polyclonal | Rabbit | Polyclonal (serum) | Human, mouse, rat | High | Variable | US$200-400 | ~65% |
| Monoclonal | Mouse, rabbit | Monoclonal (hybridoma) | Human (specific) | High | Excellent | US$300-600 | ~35% |
Key specifications: Target (SND1, Tudor-SN, p100). Host (rabbit, mouse). Clone (optional). Isotype. Reactivity (human, mouse, rat, bovine). Applications validated (WB, IHC, IF, IP, ELISA). Concentration (1 mg/mL). Format (liquid, lyophilized, Biotin conjugate, HRP conjugate, FITC conjugate). Storage (-20°C). Recommended dilution (WB 1:500-1:2000, IHC 1:100-1:500, IP 1:50-1:200). Positive control (HeLa, HEK293T, HepG2, MCF7 cell lysate, human liver tissue). LS-C669584 (LifeSpan BioSciences) specific rabbit polyclonal.
Exclusive observation (Global Info Research analysis): The SND1 antibody market is fragmented with multiple commercial suppliers (Merck, Thermo Fisher, GeneTex, LifeSpan, ProSci, Bio-Rad, Novus, ABclonal, Bethyl, Proteintech, St John’s). Niche primary antibody suppliers. LS-C669584 (LifeSpan) specific polyclonal. Chinese suppliers (Biobyt, Jingjie PTM BioLab, Wuhan Fine Biotech, Beijing Solarbio) lower cost (20-40% less), gaining domestic share. Validation data, customer reviews influence purchase (CiteAb, Biocompare). Conjugated antibodies (Biotin, HRP, FITC) eliminate secondary antibody step, saving time.
User case – Western Blot (December 2025): Cancer research lab (Europe) validates SND1 knockdown in hepatoma cell line (HepG2) using siRNA. RIPA lysate, SDS-PAGE, transfer, primary antibody (LifeSpan LS-C669584 rabbit polyclonal, 1:1000), secondary HRP-conjugated anti-rabbit IgG. Detection ECL (Enhanced Chemiluminescence). Loading control GAPDH.
User case – Immunohistochemistry (IHC) (January 2026): Pathology lab (China) stains hepatocellular carcinoma (HCC) tissue microarray (TMA). FFPE sections, citrate antigen retrieval, primary antibody (Proteintech SND1 rabbit polyclonal, 1:200), DAB detection. Scoring nuclear/cytoplasmic staining.
3. Technical Challenges
Antibody specificity validation – SND1 shares domains with other Tudor domain proteins (TDRD3, SMN). Cross-reactivity risk. Knockdown/knockout validation.
Lot-to-lot variability (polyclonal) – Polyclonal antibody from immunized rabbit, each bleed different titer. Manufacturer bulk lot purchase.
Technical difficulty – IP-MS (Immunoprecipitation-Mass Spectrometry) compatibility: SND1 antibody must be suitable for native IP (Protein A/G agarose). Cross-linking antibody to beads. Mass spectrometry requires low background.
Technical development (October 2025): ABclonal Technology introduced recombinant rabbit monoclonal SND1 antibody (animal-free, consistent, high specificity). Reduced cross-reactivity, validated for IHC, WB, IP, IF. Price premium (US$450 per 100µL).
4. Competitive Landscape
Key players include: Merck (Germany – Sigma), Thermo Fisher Scientific (US – Pierce, Invitrogen), GeneTex (US – antibodies), LifeSpan BioSciences (US – LS-C669584), Leading Biology (US), RayBiotech (US), ProSci (US), Bio-Rad (US – antibodies), Aviva Systems Biology (US), Novus Biologicals (US), ABclonal Technology (US/China), Bethyl Laboratories (US), Proteintech Group (US/China – large catalog), St John’s Laboratory (UK), Biobyt (China), Jingjie PTM BioLab (China), Wuhan Fine Biotech (China), Beijing Solarbio (China). Proteintech, Abcam (not listed) large catalog suppliers.
Regional dynamics: North America (LifeSpan, Novus, ProSci, Bethyl, Proteintech US office) largest market. Europe (St John’s). China (Biobyt, Jingjie, Wuhan Fine, Solarbio) domestic.
5. Outlook
SND1 antibody market will grow at 6.0% CAGR to US$48 million by 2032, driven by cancer research (SND1 as oncogene), RNAi biology, and viral pathogenesis. Technology trends: recombinant monoclonal (consistent), multiplex IHC, spatial proteomics, and high-throughput screening (HTS) antibody arrays. Asia-Pacific growth 7-8% CAGR.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
